Skip to main content
SpringerLink
Log in

Targeted Therapy of Acute Myeloid Leukemia

  • Book
  • © 2015

Overview

Editors:
  1. Michael Andreeff

    1. Dept. Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Presents updated contemporary classification systems of myeloid leukemias, their genetic defects and the proteomic alterations characteristic of acute myeloid leukemia
  • Summarizes and interprets targeted in acute myeloid therapies, along with future therapeutics
  • Serves as a useful guideline to scientists, translational researchers and clinicians in the field
  • Includes supplementary material: sn.pub/extras

Part of the book series: Current Cancer Research (CUCR)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (44 chapters)

  1. Front Matter

    Pages i-xix
    Download chapter PDF

  2. Genetics and Classification of Acute Myeloid Leukemia

    • Alison R. Walker, Guido Marcucci
    Pages 1-25

  3. The Use of “Omics” to Guide the Selection of Targeted Therapy

    • Steven M. Kornblau
    Pages 27-43

  4. Apoptosis

    1. Front Matter

      Pages 45-45
      Download chapter PDF

    2. Roles of Apoptosis-Regulating Bcl-2 Family Genes in AML

      • John C. Reed
      Pages 47-65

    3. Bcl-2 Family: Translational Aspects

      • Prithviraj Bose, Steven Grant
      Pages 67-94

    4. IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia

      • Bing Z. Carter, Michael Andreeff
      Pages 95-121

    5. TP53 Mutations in Acute Myeloid Leukemia

      • Ulrike Bacher, Claudia Haferlach, Vera Grossmann, Susanne Schnittger, Torsten Haferlach
      Pages 123-133

    6. Targeting p53 Tumor Suppressor for AML Therapy

      • Kojima Kensuke, Lyubomir T. Vassilev
      Pages 135-150

    7. AML-Selective Apoptosis Induction by Rationally Designed Death Ligand Fusion Proteins

      • Edwin Bremer, Wijnand Helfrich
      Pages 151-173

  5. Signaling

    1. Front Matter

      Pages 175-175
      Download chapter PDF

    2. PIM Kinases in AML

      • Lisa S. Chen, Varsha Gandhi
      Pages 177-199

    3. Development of Midostaurin as a Tyrosine Kinase Inhibitor

      • Gabriela Motyckova, Richard M. Stone
      Pages 201-214

    4. FLT3 in AML

      • Naval Daver, Farhad Ravandi
      Pages 215-231

    5. FLT3-ITD. Clinical (Sorafenib/AC220)

      • Naveen Pemmaraju, Jorge Eduardo Cortes
      Pages 233-249

    6. Nucleophosmin (NPM1)

      • Ramesh Balusu, Warren Fiskus, Kapil N. Bhalla
      Pages 251-273

    7. Raf/MEK/ERK Signaling

      • James A. McCubrey, Linda S. Steelman, Jörg Bäsecke, Alberto M. Martelli
      Pages 275-305

    8. The Role of Translational Medicine in Optimization of Therapies Targeting the RAS-MAP Kinase Pathway

      • Judith S. Sebolt-Leopold
      Pages 307-324

    9. Clinical Use of Farnesyltransferase Inhibitors

      • Chezi Ganzel, Jacob M. Rowe
      Pages 325-333

    10. The PI3K-AKT-mTOR Signaling Network in AML

      • Brandon Beagle, David A. Fruman
      Pages 335-362
Back to top

Keywords

About this book

This book provides an unprecedented overview of "Targeted Therapies" for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make "leukemia history" in the near future.

Editors and Affiliations

  • Dept. Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA

    Michael Andreeff

Bibliographic Information

  • Book Title: Targeted Therapy of Acute Myeloid Leukemia

  • Editors: Michael Andreeff

  • Series Title: Current Cancer Research

  • DOI: https://doi.org/10.1007/978-1-4939-1393-0

  • Publisher: Springer New York, NY

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer-Verlag New York 2015

  • Hardcover ISBN: 978-1-4939-1392-3Published: 21 November 2014

  • Softcover ISBN: 978-1-4939-3989-3Published: 10 September 2016

  • eBook ISBN: 978-1-4939-1393-0Published: 20 November 2014

  • Series ISSN: 2199-2584

  • Series E-ISSN: 2199-2592

  • Edition Number: 1

  • Number of Pages: XIX, 826

  • Number of Illustrations: 16 b/w illustrations, 46 illustrations in colour

  • Topics: Cancer Research, Pharmacology/Toxicology, Cell Biology, Microbiology

Publish with us

Policies and ethics

Back to top

Search

Navigation